AstraZeneca said Tuesday that its infant immunisation against respiratory syncytial virus, developed with the help of Sanofi, has won approval in China. The drugmakers have jointly developed an RSV vaccination for infants and toddlers called Beyfortus, which has already been approved for use in the EU and the US.